Therapeutic leukocytapheresis in inflammatory bowel disease: clinical efficacy and mechanisms of action.
Intense infiltration of the intestinal mucosa by activated leukocytes is a hallmark of inflammatory bowel disease (IBD). Therefore, removal of circulating leukocytes may be an attractive approach for treating IBD. Leukocytapheresis with Cellsorba, a column of polyethylenephtarate fibers that captures monocytes, granulocytes and lymphocytes, has been used to treat IBD, particularly ulcerative colitis, in Japan and Europe. This article reviews the clinical efficacy and safety data and the mechanisms of action of leukocytapheresis in IBD. Although the majority of clinical studies enrolled only small numbers of patients and had open-labeled designs, leukocytapheresis showed clinical efficacy with an excellent safety profile. Leukocytapheresis depletes granulocytes, monocytes, lymphocytes and platelets, alters cell population profiles, modulates cytokine production, and induces bone marrow-derived cells. In conclusion, leukocytapheresis exerts anti-inflammatory and tissue-repairing effects on the intestinal mucosa in IBD. Further studies are needed to explain the exact mechanism of action and to determine the true efficacy of this approach.
Mitsuyama
Keiichi
K
Department of Medicine, Kurume University School of Medicine, Japan. ibd@med.kurume-u.ac.jp
Sata
Michio
M
D002465:Cell Movement; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000097:blood; D006098:Granulocytes / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000097:blood / Q000473:pathology / Q000628:therapy*; D007413:Intestinal Mucosa / Q000473:pathology; D007937:Leukapheresis / Q000295:instrumentation / Q000379:methods*; D008214:Lymphocytes / Q000378:metabolism* / Q000473:pathology; D009000:Monocytes / Q000378:metabolism* / Q000473:pathology; D011095:Polyethylenes / Q000627:therapeutic use; D016896:Treatment Outcome
D016207:Cytokines; D011095:Polyethylenes